

Anti-SP1 (pT453) Antibody

Rabbit polyclonal antibody to SP1 (pT453)

Catalog # AP60398

Product Information

Application	WB, IF/IC, IHC
Primary Accession	P08047
Other Accession	O89090
Reactivity	Human, Mouse, Rat, Monkey, Chicken, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	80693

Additional Information

Gene ID	6667
Other Names	TSFP1; Transcription factor Sp1
Target/Specificity	Recognizes endogenous levels of SP1 (pT453) protein.
Dilution	WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500), ChIP (Use at an assay dependent concentration) IF/IC~~N/A IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500), ChIP (Use at an assay dependent concentration)
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name	SP1
Synonyms	TSFP1
Function	Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Also binds the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by

inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component BMAL1 (PubMed:[10391891](#), PubMed:[11371615](#), PubMed:[11904305](#), PubMed:[14593115](#), PubMed:[16377629](#), PubMed:[16478997](#), PubMed:[16943418](#), PubMed:[17049555](#), PubMed:[18171990](#), PubMed:[18199680](#), PubMed:[18239466](#), PubMed:[18513490](#), PubMed:[18619531](#), PubMed:[19193796](#), PubMed:[20091743](#), PubMed:[21046154](#), PubMed:[21798247](#)). Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity).

Cellular Location

Nucleus. Cytoplasm. Note=Nuclear location is governed by glycosylated/phosphorylated states. Insulin promotes nuclear location, while glucagon favors cytoplasmic location


Tissue Location

Up-regulated in adenocarcinomas of the stomach (at protein level). Isoform 3 is ubiquitously expressed at low levels


Background

KLH-conjugated synthetic peptide encompassing a sequence within the center region of human SP1 (pT453). The exact sequence is proprietary.

Images




Western blot analysis of SP1 (pT453) expression in H1688 (A) whole cell lysates.



Immunohistochemical analysis of SP1 (pT453) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Immunofluorescent analysis of SP1 (pT453) staining in Jurkat cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified



chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.